Severo Ochoa Programme 2018-2022 Health NEWS

Thursday, 10 June 2021

Novel biosensing platform for point-of-care analysis of complex samples without pretreatment

A paper published in “Analytical Chemistry” describes an enhanced biosensing platform based on lateral-flow-assay (LFA) for point-of-care analysis. Cheap, easy to use and portable as LFA, this paper-based electrophoretic bioassay (PEB) allows performing tests on viscous samples, as whole blood, without the need for pretreatment steps. This research was developed by members of the ICN2 Nanobioelectronics and Biosensors Group.

Tuesday, 01 June 2021

Novel nano-encapsulation approach for efficient dopamine delivery in Parkinson’s treatment

In a study just published in “ACS Nano”, polymeric nanoparticles inspired by natural neuromelanin were used to encapsulate dopamine and to be administered via intranasal to reach the brain for Parkinson’s disease treatment. This work was coordinated by ICN2 Group Leader Dr Daniel Ruiz-Molina and Dr Julia Lorenzo, Group Leader at the Institute of Biotechnology and Biomedicine (IBB) of UAB, and developed in collaboration with the group led by Prof. Miquel Vila at VHIR. 

Friday, 26 March 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies

INBRAIN Neuroelectronics, a spin-off company of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, announces a €14.35M Series A investment, co-led by Asabys Partners and Alta Life Sciences, and joined by Vsquared Ventures (Germany), TruVenturo (Germany) and CDTI (Spanish Ministry of Science and Innovation). INBRAIN has the mission to develop intelligent neuroelectronic therapies based on graphene technology for application in patients with epilepsy, Parkinson’s and other brain related disorders.

Monday, 15 March 2021

Nanotechnology provides new solutions for microbiome-based diagnostics and personalized medicine

A review recently published in "Advanced Materials" by members of the ICN2 Nanobioelectronics and Biosensors group, led by ICREA Prof. Arben Merkoçi, in collaboration with other institutes and in the framework of the MICROB-PREDICT project, presents the potentialities of nanotechnology for developing biosensors for the monitoring of the human microbiome. These studies can open new paths for the diagnostics of diseases such as cirrhosis, acute liver failure and colorectal cancer, and to personalized therapy.

Tuesday, 02 March 2021

Graphene-based neural interface allows improved brain activity mapping

A study recently published in "Nature Communication" demonstrates that graphene-based active sensor arrays are a mature technology for large-scale application in wide frequency band neural sensing interfaces. This work was developed by researchers from various institutes and a company that are part of the EU Graphene Flagship – including the ICN2.

Tuesday, 02 March 2021

The ICN2 is involved in 3 programmes suggested by the Catalan Government to access the Next Generation EU funds

The Secretariat of Universities and Research of the Department of Business and Knowledge has submitted to the Spanish government a proposal for 120 million Euros, of which the Catalan government could co-finance over 59 million Euros. The programs, led by agents of the Catalan knowledge system, are in quantum communication, energy and green hydrogen, agri-food, biodiversity, astrophysics, marine sciences, advanced materials and biotechnology applied to health.

Monday, 27 April 2020

Prof. Kostas Kostarelos claims scientists should be back in the labs as ‘essentials’ to face COVID-19 emergency

In an opinion article published today by Nature Nanotechnology, Prof. Kostas Kostarelos shares his views on what may be going wrong in the fight against COVID-19 and how the nanoscience community could contribute. He suggests applying the three key principles in managing an individual cancer patient: early detection, monitoring and targeting. Prof. Kostas Kostarelos recently became Senior Group Leader at the ICN2 after a long-standing collaboration that is now reinforced through the ICN2 Severo Ochoa talent attraction strategy. He will continue directing the Nanomedicine Lab at the University of Manchester, while also leading the new ICN2 Nanomedicine Group.

Monday, 06 April 2020

Prof. Laura Lechuga explains the CoNVaT project on RTVE

In the edition of 4 April of the “Informe Semanal”, weekly in-depth news show of the RTVE, Prof. Laura Lechuga presented CoNVaT, the European funded project that she leads, which aims at the development of a fast, cheap and handy test device for the diagnosis of the COVID-19.

Thursday, 02 April 2020

La Vanguardia highlights the diagnostic tests by Paperdrop Dx

Paperdrop Diagnostics is the ICN2 and ICREA spin-off devoted to the development of rapid diagnostic tests based on paper microfluidics. La Vanguardia remarks their new test for ischemic stroke, based on the evaluation of microRNA, and their efforts to produce a Covid-19 test from this technology.

Wednesday, 01 April 2020

CoNVaT will design a new diagnostic system for COVID-19 with the best current technologies

The ICN2 Nanobiosensors and Bioanalytical Applications Group, led by Prof. Laura Lechuga, coordinates a European project with a budget over 2 million euros. They have become an international reference in COVID-19 diagnostics and have prepared a report for the Ministry of Science and Innovation analysing the characteristics, advantages and limitations of current detection systems for diagnosing COVID-19.

Tuesday, 17 March 2020

The ICN2 minimises its activity due to the State of Alarm

Since last week the ICN2 has adapted its activity level to the quickly evolving context caused by the COVID-19 disease spread. As per today, only very few ICN2 members are allowed to enter the ICN2 facilities, including the research Group led by Prof. Laura Lechuga who is leading the CONVAT project to design a tool to diagnose COVID-19. Most of the personnel will remain active working, contributing to fight this spreading disease by following the indications published by authorities as well as through research.

Friday, 06 March 2020

The ICN2 leads a European project to diagnose the COVID-19 disease in 30 minutes

The CONVAT project, led and coordinated by Prof. Laura M. Lechuga, CSIC Research Professor at the Catalan Institute of Nanoscience and Nanotechnology (ICN2), will develop a point-of-care platform for rapid diagnosis and monitoring of coronavirus. The biosensor device will also allow the analysis of different types of coronavirus present in reservoir animals, such as bats, to monitor the evolution of these viruses and prevent future infectious outbreaks in humans.

Tuesday, 11 February 2020

DOC-FAM doctoral students celebrate a welcome event

ICMAB coordinates CSIC’s DOC-FAM excellence DOCtoral training programme in Functional Advanced Materials, which is providing excellent doctoral students to collaborator institutions such as the ICN2. The predoctoral students hired in the second call of this H2020-MSCA-COFUND action offered a short presentation about their research and personal objectives. Two of them, Alejandro Astúa and Alejandro Astúa work at the ICN2 and were supported by their group leaders, Prof. Laura Lechuga and Prof. Pedro Gómez, respectively.

Monday, 10 February 2020

Cerium oxide nanoparticles may improve hepatocellular carcinoma prognosis

This liver cancer is the most common and is in need of new therapeutic approaches. A long-term collaboration between IDIBAPS and ICN2, led by Prof. Wladimiro Jiménez and Prof. ICREA Víctor F. Puntes, has demonstrated that the administration of cerium oxide nanoparticles in a rat animal model can compete with the best currently available treatments. The Research published in Hepatology shows that human tissues also absorb and retain the nanoparticles, making them a potential and promising new drug strategy.

Tuesday, 04 February 2020

Vote for our brain graphene-based devices!

La Vanguardia has selected the brain-computer interfaces designed by the ICN2 and IMB-CNM-CSIC, with a long list of close collaborators, among the candidates to win its prestigious award Vanguardia de la Ciencia. Help us disseminate the fight against epilepsy, migraine or brain damage with nanotechnology. The winner will be one of the 8 candidates that will be selected through popular vote.